Tuesday, June 16, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
New Trial Planned In Cardiac Surgery-Associated Acute Kidney Injury. Cadrenal announced plans for a Phase 2a trial in Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKD). The trial is designed to demonstrate proof of concept and generate data on safety, measures of renal injury, and biomarkers of the 12-LOX inflammatory pathway. This would provide data on CAD-1005 in CSA-AKD as well as its other indications in development.
Trial Design. The trial is expected to test CAD-1005 using its intravenous formulation in Intensive Care Unit (ICU) settings later in FY2026. This data could be used in several development indications for CAS-1005, including the HIT (heparin-induced thrombocytopenia) indication, which is planned to begin Phase 3 later in FY2026-27. At this time, Cadrenal plans to use the data to form a development partnership for the CSA-AKI indication.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.